STAT

Opinion: How one pharmaceutical company is reinventing the clinical trial

It's time to make clinical trials more rewarding for patients and investigators, and speed the delivery of new therapies. Here's how one company is doing that.

Millions of Americans— most of us, in fact — rely on medications, from prescription drugs for high cholesterol, diabetes, asthma, cancer, and the like to over-the-counter medicines for allergy, acne, and other conditions.

While the myriad medications we take differ from one another, they have something important in common: Before they were sold to a single person, they were tested by people who volunteered to take part in clinical trials. It was only after these trials demonstrated the drugs had favorable benefit-risk profiles that they were able to make their way to pharmacy shelves.

Clinical trials are as essential today as drug discovery for bringing new drugs to market. But while new tools and technologies have helped advance techniques for new drug discovery, we’ve seen far less innovation in clinical trials. The process continues to be

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks